An overview of some potential immunotherapeutic options against COVID-19
Authors:
- 1 June 2021
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 95, 107516
Abstract
No abstract availableKeywords
This publication has 208 references indexed in Scilit:
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus InfectionPLOS ONE, 2013
- Siglecs as sensors of self in innate and adaptive immune responsesAnnals of the New York Academy of Sciences, 2012
- A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*Critical Care Medicine, 2012
- Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivoJournal of Experimental Medicine, 2009
- CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patternsTrends in Immunology, 2009
- Rhesus Theta-Defensin Prevents Death in a Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Pulmonary DiseaseJournal of Virology, 2009
- CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune ResponsesScience, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cellsCellular Immunology, 2009
- Identification of pulmonary Oct-4 + stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitroProceedings of the National Academy of Sciences, 2006